Fig. 1From: Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosisSummary of bone marrow fibrosis changes from baseline, by treatment cycle (*Persistent grade 3)Back to article page